

Community Prevalence of SARS-CoV-2 in England: Results from the ONS Coronavirus Infection Survey Pilot

Koen B Pouwels, Thomas House, Julie V Robotham, Paul J Birrell, Andrew Gelman, Nikola Bowers, Ian Boreham, Heledd Thomas, James Lewis, Iain Bell, John I Bell, John N Newton, Jeremy Farrar, Ian Diamond, Pete Benton, Ann Sarah Walker, and the COVID-19 Infection Survey team

Supplementary File 1

This file contains mathematical and statistical details of the analysis and its interpretation.

1 Models estimated in the paper

Dynamic MRP

The regression model that was used for the dynamic multilevel model and post-stratification (MRP) analysis was a Bayesian multilevel generalised additive model (GAMM) with a complementary loglog link implemented using the `rstanarm` package.[1-2] Sex was modelled as a fixed effect as it has only 2 levels, while age (5 levels) and region (9 levels) were modelled as random effects. This model was implemented using the following syntax:

```
stan_gamm4(result ~ s(time, by=region, k=5) +
sex, random = ~(1|age) + (1|region),
family = binomial(link="cloglog"),
data = data, iter = 3000, cores = 4,
prior = normal(0,0.5), prior_covariance
= decov(shape = 1, scale = 1),
control=list(adapt_delta=0.95)
```

Associations between variables and testing positive

To assess whether particular subgroups are more likely to test positive for SARS-CoV-2 viral RNA we performed an additional analysis including variables on which we did not post-stratify. We used the same model as for the dynamic MRP but in working aged individuals only (16-74 years inclusive as defined in the Labour Force Survey) with these additional variables included as fixed covariates and age modelled as a continuous variable, using a thin-plate spline (again with $k=5$), instead of a categorical variable. Associated syntax and results can be found in Table 1 in the main text and in supplementary file 3.

Presence of symptoms among those testing positive

A Bayesian ordinal (adjacent category family) regression model with the following outcomes: 1) negative test, 2) positive test and no reported symptoms, and 3) positive test and reported symptoms was used for evaluating the association between potential risk factors and this ordinal outcome variable. The model allowed for category-specific effects for the variables with clear evidence of an effect on a positive test (regardless of presence of symptoms). This ordinal regression model was fitted using the `brms` package in R version 3.6.1. [3] This model was implemented using the following syntax:

```
priors <- c(set_prior("normal(0,1)", class="b", coef= "work_locationWorkingOutsideofyourHome"),
set_prior("normal(0,1)", class="b", coef= "work_locationBoth"),
set_prior("normal(0,1)", class="b", coef= "work_locationNotapplicable"),
set_prior("normal(0,1)", class="b", coef= "patient_facing1"),
set_prior("normal(0,1)", class="b", coef= "resident_facing1"),
set_prior("gamma(1,1)",class="sd", group="region", coef="Intercept),
set_prior("normal(7,1)",class="Intercept",coef="1"),
set_prior("normal(8,2)",class="Intercept",coef="2"))
```

```
brm(test_symp ~ cs(work_location) + cs(patient_facing) + cs(resident_facing) + (1|region),
family=acat(link="cloglog", threshold="flexible"), data=data, control=list(adapt_delta=0.95),cores=4, chains=4,
prior=priors)
```

4 Epidemiological interpretation of the complementary log-log link function when focusing on associations between variables and testing positive for the presence of SARS-CoV-2 RNA.

Our regression model operates at the individual level; in particular, we assume that there are n swabs taken, and the i -th of these is associated with time t_i , English region e_i , and a vector of other covariates x_i . These covariates are as detailed in the main text: age; work etc. The probability of the i -th swab being positive is then given by a generalised linear model (generalised additive model).

$$\pi_i = p(x_i, e_i, t_i) = g^{-1}(s_{e_i}(t_i) + \beta \cdot x_i + \zeta_{e_i}). \quad (1)$$

Here, s_{e_i} is the time smoother for the region e , β is the vector of regression coefficients, and ζ_e is the random effect for region e , with these effects assumed i.i.d. with $\zeta_e \sim N(0, \sigma^2)$. The likelihood function for this model given observations $y_i = 1$ for a positive swab and $y_i = 0$ for negative, is then

$$L = \prod_{i=1}^n \pi_i^{y_i} (1 - \pi_i)^{1-y_i}. \quad (2)$$

Now suppose that the individual i acquires infection at a rate $\lambda_i(t)$, known as the *force of infection* in infectious disease modelling. The Chapman-Kolmogorov equation, using dots for time derivatives, is:

$$\dot{\pi}_i(t) = (1 - \pi_i)\lambda_i(t). \quad (3)$$

This has solution

$$\pi_i = 1 - \exp\left(-\int_{u=0}^t \lambda_i(u) du\right). \quad (4)$$

If we choose a complementary log-log link function

$$g(x) = \log(-\log(1 - x)) \quad (5)$$

in (1), and assume that

$$\lambda_i(t) = \phi_i \lambda_{e_i}(t). \quad (6)$$

in (5), then we get

$$\pi_i = 1 - \exp\left(-\phi \int_{u=0}^t \lambda_{e_i}(u) du\right) = 1 - \exp\left(-\exp(\beta \cdot x_i) \exp(s_{e_i}(t_i)) \exp(\zeta_{e_i})\right). \quad (7)$$

This implies that

$$\phi_i \propto \prod_a e^{\beta_a x_{ia}}, \quad (8)$$

and so we quote the value of $\exp(\beta_a)$ for the a -th covariate, with 1 as reference, since this is interpretable as the relative exposure to infectious risk.

5 Calculation of growth rates and doubling / halving times

From (7), suppressing dependence on region, we also obtain

$$\int_{u=1}^t \lambda(u) du = \exp(s(t)) . \quad (9)$$

Then the standard definition of the instantaneous epidemic growth rate gives, when combined with differentiating (9) twice and using Leibniz's rule,

$$r(t) = \frac{\dot{\lambda}(t)}{\lambda} = \frac{((\dot{s}(t))^2 + \ddot{s}(t)) \exp(s(t))}{\dot{s}(t) \exp(s(t))} = \dot{s}(t) + \frac{\ddot{s}(t)}{\dot{s}(t)} . \quad (10)$$

6 Figures and tables




Fig S1. Comparison of using all data (34,992 participants) for the multi-level regression with post-stratification for estimation of the percentage of inhabitants testing positive over time versus use one randomly selected person per household (16,772 participants). The shaded area falls within the 95% credible intervals.




Fig S2. Smooth term for age obtained using a multivariable Bayesian regression model estimating associations between variables and test positivity. The shaded area falls within the 95% credible intervals.




Fig S3. Smooth term for time by different work locations obtained using a multivariable Bayesian regression model estimating associations between variables and test positivity. The shaded area falls within the 95% credible intervals.




Fig S4. Smooth term for time by job-type involving direct contact with patients or not obtained using a multivariable Bayesian regression model estimating associations between variables and test positivity. The shaded area falls within the 95% credible intervals.




Fig S5. Percentage of participants reporting symptoms when testing positive for the presence of SARS-CoV-2 over time. The shaded area falls within the 95% credible intervals.

7 References

1. <https://cran.r-project.org/web/packages/rstanarm/vignettes/mrp.html>
2. [http://www.stat.columbia.edu/~gelman/research/unpublished/MRT\(1\).pdf](http://www.stat.columbia.edu/~gelman/research/unpublished/MRT(1).pdf)
3. <https://www.jstatsoft.org/article/view/v080i01>

8 STROBE checklist

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-7
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	4-5

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	5-6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	6-7
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Figure 1, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	5-6
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	7, Figure 2
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	7
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-8, Table 1
		(b) Report category boundaries when continuous variables were categorized	Table 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7-8
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10-11
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	9-11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.